Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trialMark T. Drayson, Janet Dunn, Kerry Raynes et al.|The Lancet Oncology|2019Cited by 160
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AMLJad Othman, Richard Dillon, Steven Knapper et al.|Leukemia|2023Cited by 48
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Michael J. Austin et al.|Blood Neoplasia|2024Cited by 36
Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapyJad Othman, Richard Dillon, Pramila Krishnamurthy et al.|Blood Advances|2024Cited by 10